Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Olipudase alfa in ASMD
NCT02004691Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2015
- Primary completion
- Mar 2021
- Modality
- Replacement Enzymes
- Countries
- 17
01
Overview
A Phase 3 trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Started Dec 2015; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on NCT02004691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02004691.